When Antidepressants Don’t Work: Esketamine for Treatment-Resistant Depression

Key Takeaways: 

• Treatment-resistant depression (TRD) is common and real: About one in three people with major depressive disorder don’t respond adequately to at least two properly prescribed antidepressants—and this isn’t a personal failure. 

• TRD means a different approach is needed: Depression involves multiple brain systems, and for some people, traditional serotonin-based medications simply don’t target the pathways driving their symptoms. 

• New, faster-acting treatments offer hope: FDA-approved options like Spravato (esketamine) work through the glutamate system and can provide relief in days rather than weeks or months. 

• Spravato is specifically approved for TRD: It’s administered in a certified medical setting, used alongside an oral antidepressant, and backed by strong clinical evidence. 

• Effective treatment can restore function and hope: Many people with TRD experience meaningful symptom relief, improved daily functioning, and renewed motivation when they find the right advanced treatment. 

Question: 

What is treatment-resistant depression? 

Answer: 

If you’ve tried antidepressant after antidepressant only to feel the same crushing weight of depression, you’re not alone—and you haven’t run out of options. Many people with depression do everything they’re told: they take medications as prescribed, attend appointments, and wait patiently for relief that never seems to come. Over time, that cycle can lead to exhaustion, frustration, and a deep sense of hopelessness. 

This experience has a name: treatment-resistant depression. It’s real, it’s common, and it doesn’t mean you’ve failed at recovery. It means your brain may need a different kind of treatment. 

The good news is that recent FDA-approved breakthroughs are changing what’s possible for people who thought they’d tried everything. Rapid-acting options— including treatments that work very differently from traditional antidepressants—are offering new hope. 

In this article, we’ll explain what treatment-resistant depression is, why it happens, and explore cutting-edge options like Spravato treatment, available at Footprints to Recovery Mental Health in Elgin, Illinois. 

What Is Considered Treatment-Resistant Depression? 

Treatment-resistant depression (TRD) is typically defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications, taken at the proper dose and for a sufficient length of time. Clinically, this affects about one in three people with major depression. 

If this is you, it’s important to understand something clearly: treatment resistance is not a personal failure. It doesn’t mean you didn’t try hard enough or that recovery isn’t possible. It simply means your depression requires a different approach. 

For many people, TRD feels like an endless cycle: 

• Trying medication after medication—sometimes three, four, or five or more 

• Feeling hopeful each time that “this one will work.” 

• Experiencing side effects without real relief 

• Noticing partial improvements that fade 

• Watching others get better while you remain stuck 

Over time, the impact can be profound. Depression may interfere with work, strain relationships, and make even basic daily tasks feel overwhelming. Suicide risk increases, and life can feel like it’s passing by while you remain trapped in place. 

If this sounds familiar, it may be time to look beyond traditional antidepressants. 

Why Traditional Treatments Fail for Some People 

Understanding why depression becomes treatment-resistant helps explain why a different solution may be needed. 

Depression is not caused by a single chemical imbalance. It involves multiple neurotransmitter systems and complex brain circuitry. Traditional antidepressants—such as SSRIs and SNRIs—primarily target serotonin, norepinephrine, or dopamine. While these medications help many people, they don’t address every pathway involved in depression. 

For some individuals, the underlying biology of depression simply isn’t responsive to those mechanisms. In other words, your brain may need a fundamentally different kind of treatment. 

Other contributing factors can include: 

• Co-occurring conditions such as anxiety, PTSD, ADHD, postpartum depression, or chronic major depression 

• Misdiagnosis, such as bipolar disorder being treated as unipolar depression 

• Unresolved trauma that medications alone can’t address 

Recognizing treatment resistance isn’t about blame. It’s about clarity. Once you understand why standard approaches haven’t worked, you can pursue treatments designed for how your brain actually functions. 

Fortunately, science has developed options that work through entirely different mechanisms—offering real hope where traditional antidepressants have failed. 

Beyond Traditional Antidepressants: New Hope for TRD 

When SSRIs and SNRIs don’t work, the traditional approach has often been to keep trying—switching medications, adjusting doses, or adding new drugs to the mix. Each trial can take six to eight weeks, and during that time, depression continues to disrupt your life. 

Many people with treatment-resistant depression eventually ask the same question: What if there were treatments that worked faster—and differently? 

That question has led to one of the most important advances in depression treatment in decades. 

Esketamine (Spravato): An FDA-Approved Breakthrough for Depression 

Spravato® (esketamine) is an FDA-approved treatment specifically for treatment-resistant depression. Unlike traditional antidepressants, it works on the glutamate system, not serotonin. 

What makes this so significant is speed. While conventional medications may take weeks or months to help, Spravato can begin providing relief within hours or days for some patients. 

Spravato is administered as a nasal spray in a certified medical setting and is used alongside an oral antidepressant. It’s approved for adults who have not responded to at least two antidepressant medications. 

Why Spravato Represents Real Hope: 

• A completely different mechanism of action 

• Rapid onset of symptom relief 

• Proven effectiveness in clinical trials 

• FDA-approved specifically for TRD 

• Medically supervised administration for safety 

Spravato works by targeting the NMDA receptors in the brain, increasing glutamate activity. This process promotes new neural connections and may help reverse brain changes associated with long-term depression—something traditional antidepressants don’t address. 

Esketamine treatment takes place at a certified facility with monitoring during and after each session. Most people begin with two sessions per week, and many notice improvements early in treatment, with continued sessions helping maintainbenefits. 

Esketamine vs. Ketamine: What’s the Difference? 

Ketamine and esketamine are closely related but not the same. Ketamine is an older anesthetic medication that’s used off-label to treat depression, PTSD, and chronic pain. It contains two mirror-image molecules (R-ketamine and S-ketamine) and is most often given as an IV infusion in specialty clinics. While not yet FDA-approved for depression, IV ketamine is widely used because it can produce rapid antidepressant effects, often within hours or days. 

Esketamine (brand name Spravato®) is made from only the S-ketamine portion of ketamine and is FDA-approved for treatment-resistant depression and for major depression with suicidal thoughts. It’s administered as a nasal spray in a certified behavioral health clinic and must be used alongside an oral antidepressant. Esketamine is more tightly regulated and more expensive, but it’s often covered by insurance—whereas ketamine usually isn’t.